Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP-7888 in Advanced Malignancies
NCT02498665Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Nov 2015
- Primary completion
- Aug 2018
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of adegramotide + nelatimotide in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), glioblastoma (GBM) and 6 more (3 cohorts), sponsored by Sumitomo Pharma America. Primary endpoints: Dose-Limiting Toxicities at 4 weeks, Duration of Study Treatment at 12 months and 1 more. Started Nov 2015; status: completed.
02
Drugs
adegramotide + nelatimotide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)glioblastoma (GBM)melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02498665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02498665.